pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX
Avalo Therapeutics
Avalo Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
- Founded
- 2011
- Employees
- 48
- Programs
- 17
- Drugs
- 2
- Patents
- 10
Avalo Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Avalo Therapeutics.
Avalo Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AEVI-001
Avalo Therapeutics
Attention Deficit Hyperactivity Disorder
2 trials -
AVTX-002
Avalo Therapeutics
Non-Eosinophilic Asthma
1 trial -
AVTX-009 Regimen 1
Avalo Therapeutics
Hidradenitis Suppurativa
1 trial -
CERC-002
Avalo Therapeutics
COVID-19 Pneumonia
1 trial -
CERC-301
Avalo Therapeutics
Major Depressive Disorder
2 trials -
FP01
Avalo Therapeutics
Acute Cough
1 trial -
FP01
Avalo Therapeutics
Chronic Refractory Cough
1 trial -
MDGN201 TARGTEPO
Avalo Therapeutics
Anemia of End Stage Renal Disease
1 trial -
Placebo to AVTX-009, AVTX-009
Avalo Therapeutics
Hidradenitis suppurativa (HS)
1 trial
Frequently asked questions
How many clinical projects does Avalo Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.